EHR costs cited as 3 hospitals, parent company file for bankruptcy

Three Mississippi hospitals and their parent company have filed for bankruptcy—identifying electronic health record (EHR) costs and declining revenues as primary reasons.

According to a report by the Plainview Daily Herald, nonprofit health system Curae Health recently filed for Chapter 11 bankruptcy reorganization in Nashville, Tennessee. Three of the company’s Mississippi hospitals—Gilmore Memorial Hospital, Panola Medical Center and Northwest Mississippi Regional Medical Center—are also seeking bankruptcy.

In the report, Curae Health CEO Stephen Clapp said the move was brought on by declining revenues and “higher-than-expected costs” for EHRs at the hospitals. The company was also about $70 million in debt.

“Clapp added that past revenue and profits were high enough when Curae bought the hospitals in 2017 to pay off the money the company borrowed," the report said. "But he said revenue declined and the hospitals faced higher-than-expected costs for electronic health records. He said the company saw a cash crunch, with vendors demanding payment for lagging bills, which sparked the bankruptcy filing."

To read the full report, click the link below.

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.